Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Siltuximab: first global approval.

Literature DB >> 24958337

Siltuximab: first global approval.

Anthony Markham¹, Trina Patel.
1. Adis, Auckland, New Zealand.

Abstract

The anti-interleukin-6 (IL-6) chimeric monoclonal antibody siltuximab is the first drug to be approved for the treatment of multicentric Castleman's disease (MCD) in the US and European union (EU), having gained approval under the FDA priority review program in the US and from an accelerated assessment and recommendation by the Committee for Medicinal Products for Human Use (CHMP) in the EU. Development of the drug is continuing in smoldering multiple myeloma. This article summarizes the milestones in the development of siltuximab leading to this first approval for MCD.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 24958337 DOI： 10.1007/s40265-014-0249-x

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

13 in total

1. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma.

Authors: Thomas Puchalski; Uma Prabhakar; Qun Jiao; Birge Berns; Hugh M Davis
Journal: Clin Cancer Res Date: 2010-02-23 Impact factor: 12.531

2. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.

Authors: Peter M Voorhees; Robert F Manges; Pieter Sonneveld; Sundar Jagannath; George Somlo; Amrita Krishnan; Suzanne Lentzsch; Richard C Frank; Sonja Zweegman; Pierre W Wijermans; Robert Z Orlowski; Britte Kranenburg; Brett Hall; Tineke Casneuf; Xiang Qin; Helgi van de Velde; Hong Xie; Sheeba K Thomas
Journal: Br J Haematol Date: 2013-02-25 Impact factor: 6.998

3. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.

Authors: Frits van Rhee; Katie Stone; Susann Szmania; Bart Barlogie; Zeba Singh
Journal: Clin Adv Hematol Oncol Date: 2010-07

4. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.

Authors: Jayaprakash Karkera; Hannes Steiner; Weimin Li; Viktor Skradski; Patrizia L Moser; Sabine Riethdorf; Manjula Reddy; Thomas Puchalski; Karim Safer; Uma Prabhakar; Klaus Pantel; Ming Qi; Zoran Culig
Journal: Prostate Date: 2011-02-14 Impact factor: 4.104

5. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.

Authors: Sally A Hunsucker; Valeria Magarotto; Deborah J Kuhn; Steven M Kornblau; Michael Wang; Donna M Weber; Sheeba K Thomas; Jatin J Shah; Peter M Voorhees; Hong Xie; Mark Cornfeld; Jeffrey A Nemeth; Robert Z Orlowski
Journal: Br J Haematol Date: 2011-01-17 Impact factor: 6.998

6. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.

Authors: Yuqi Guo; Jeffrey Nemeth; Colin O'Brien; Michiro Susa; Xianzhe Liu; Zhan Zhang; Edwin Choy; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal: Clin Cancer Res Date: 2010-08-10 Impact factor: 12.531

7. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.

Authors: H C van Zaanen; R P Koopmans; L A Aarden; H J Rensink; J M Stouthard; S O Warnaar; H M Lokhorst; M H van Oers
Journal: J Clin Invest Date: 1996-09-15 Impact factor: 14.808

8. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.

Authors: Peter M Voorhees; Qing Chen; George W Small; Deborah J Kuhn; Sally A Hunsucker; Jeffrey A Nemeth; Robert Z Orlowski
Journal: Br J Haematol Date: 2008-03-06 Impact factor: 6.998

Review 9. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Authors: David C Fajgenbaum; Frits van Rhee; Christopher S Nabel
Journal: Blood Date: 2014-03-12 Impact factor: 22.113

Review 10. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Authors: Mohit Trikha; Robert Corringham; Bernard Klein; Jean-François Rossi
Journal: Clin Cancer Res Date: 2003-10-15 Impact factor: 12.531

13 in total

1. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.

Authors: Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Denise Whitby; Victoria Wang; Stefania Pittaluga; Deirdre O'Mahony; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal: Blood Date: 2014-10-20 Impact factor: 22.113

Review 2. Review of siltuximab in the treatment of multicentric Castleman's disease.

Authors: Shayna Sarosiek; Ruchit Shah; Nikhil C Munshi
Journal: Ther Adv Hematol Date: 2016-06-23

3. Treatment of Cystic Craniopharyngiomas: An Update.

Authors: Federico Bianchi; Alberto Benato; Luca Massimi
Journal: Adv Tech Stand Neurosurg Date: 2022

Review 4. Clinical development of siltuximab.

Authors: Christine C Davis; Katherine S Shah; Mary Jo Lechowicz
Journal: Curr Oncol Rep Date: 2015-07 Impact factor: 5.945

Review 5. Siltuximab (CNTO 328): a promising option for human malignancies.

Authors: Runzhe Chen; Baoan Chen
Journal: Drug Des Devel Ther Date: 2015-07-02 Impact factor: 4.162

Review 6. Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.

Authors: Peleg Rider; Yaron Carmi; Idan Cohen
Journal: Int J Cell Biol Date: 2016-12-19

Review 7. Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.

Authors: Caterina Musolino; Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Giovanni Pioggia; Sebastiano Gangemi
Journal: Mediators Inflamm Date: 2017-09-26 Impact factor: 4.711